ExeVir Bio

There is no urgent need to administer booster COVID-19 vaccines to fully vaccinated people in the general European population, because evidence to date shows that all vaccines authorized in the EU are

Cash is flooding into biopharmaceuticals, but regenerative medicine companies in particular have raked in large sums of cash – in part, because of the high upfront investment in manufacturing, but als

In what it describes as a “substantial boost” for the UK’s vaccine manufacturing capacity, the government has announced an additional £100m (US$130m) in funding for a state-of-the-art production cente

In a candid conversation, Chris Buyse talks about moving on from ThromboGenics – a biotech that managed to discover and develop a new drug, and get it approved and licensed, only to fall at the final